Neurotrophic activities and therapeutic experience with a brain derived peptide preparation

  • M. Windisch
  • A. Gschanes
  • B. Hutter-Paier
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 53)


In spite that the use of naturally occurring neurotrophic factors like NGF, BDNF, CNTF, GDNF and others for treatment of neuro-degenerative disorders seems promising because of their pharmacological properties, until now no large scale clinical trials have been published. One of the reasons is that these molecules are unable to penetrate through the blood brain barrier, making invasive application strategies like intracere-broventricular infusion necessary. Another one is the fact that in first clinical studies, several undesirable side-effects like hyperalgesia or weight loss have been reported. Major efforts are now put into development of improved application procedures and in treatment protocols for avoiding the known side-effects.

Already 7 years ago it has been demonstrated that Cerebrolysin®, a peptidergic drug, produced from purified brain proteins by standardized enzymatic breakdown, containing biologically active peptides, is exerting nerve growth factor like activity on neurons from dorsal root ganglia. Still ongoing investigations are showing growth promoting efficacy of this drug in different neuronal populations from peripheral and central nervous system. The current findings are in accordance with several older publications, enabling now a more clear interpretation of these findings. In addition to the direct neurotrophic effect, the drug also shows clear neuroprotective properties after different types of lesion in vitro and in vivo, resembling the pharmacological activities of naturally occurring nerve growth factors. Neurotrophic and neuroprotective efficacy has been shown with a broad variety of methods in different models and it is remarkable that all biochemical and morphological drug dependent alterations are resulting in improvements of learning and memory.

Because of these experimental results, clinical trials using cerebrolysin in Alzheimer’s patients have been performed, demonstrating a quick improvement in the overall state of the patients, particularly enhancing the cognitive performance. It is remarkable that these effects are long lasting after cessation of the active treatment procedure. Even 6 months after stop of drug application, improvements in AD-patients are detectable. Therefore it is concluded that cerebrolysin is able to induce repair phenomena, resulting in long term stabilization. In contrast to the naturally occurring growth factors, tolerability of this drug is extremely high, without any reports about serious side-effects in these clinical studies.


Nerve Growth Factor Dorsal Root Ganglion Brain Derive Neurotrophic Factor Spatial Navigation Neurotrophic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7: 213–221PubMedGoogle Scholar
  2. Albrecht E, Hingel S, Crailsheim K, Windisch M (1993) The effects of cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brainstem of chick embryos in vitro. Adv Biosci 87: 341–442Google Scholar
  3. Anand R, Gharabawi G (1996) Clinical development of ExelonTM (ENA-713): the Adena programme. J Drug Dev Clin Pract 8: 117–122Google Scholar
  4. Barde YA (1989) Trophic factors and neuronal survival. Neuron 2: 1525–1534PubMedCrossRefGoogle Scholar
  5. Boado RJ (1995) Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 197: 179–182PubMedCrossRefGoogle Scholar
  6. Boado RJ (1996) Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 220: 53–56PubMedCrossRefGoogle Scholar
  7. Boado RJ, Wu D, Pardridge WM, Windisch M (1997) In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. J Neurol Sci 150: 77CrossRefGoogle Scholar
  8. Boissiere F, Hunot S, Faucheeux B, Mouatt-Prigent A, Agid Y, Hirsch EC (1997) Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer’s disease. Dementia 8: 1–8Google Scholar
  9. Cummings J, Bieber F, Mas J, Orazem J, Gulanski B (1997) Metrifonate in Alzheimer’s disease: results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. Wiley, New York, pp 659–669Google Scholar
  10. Francis-Turner L, Valouskova V (1996a) Nerve growth factor and nootropic drug cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1–4CrossRefGoogle Scholar
  11. Francis-Turner L, Valouskova V, Mokry J (1996b) Long-term effect of NGF, b-FGF and cerebrolysin on the spatial memory after fimbria-fornix lesion in rats. J Neural Transm 47: 277CrossRefGoogle Scholar
  12. Gavrilova SI, Selezneva ND, Kolykhalov IV, Roschina IF, Jarikov GA (1997) Efficacy of cerebrolysin in Alzheimer’s disease. Eur Neuropsychopharmacol 7: 4CrossRefGoogle Scholar
  13. Gschanes A, Windisch M (1996) The influence of cerebrolysin and EO21 on spatial navigation of young rats. J Neural Transm 47: 278CrossRefGoogle Scholar
  14. Gschanes A, Windisch M (1997) The influence of brain-derived peptides on spatial navigation of young and adult rats. Soc Neurosci Abstr 23: 1842Google Scholar
  15. Hampson DR, Windisch M, Baskys A (1997) Increased binding of BDNF to trkB induced by the antidementia drug cerebrolysin. Soc Neurosci Abstr 23: 1896Google Scholar
  16. Hefti F (1994) Growth factors and neurodegeneration. In: Calne D (ed) Neuro-degenerative diseases. Saunders, Philadelphia, pp 177–194Google Scholar
  17. Hutter-Paier B, Eggenreich U, Windisch M (1996) Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats. Arzneimit-telforschung/Drug Res 46/1: 237–241Google Scholar
  18. Hutter-Paier B, Grygar E, Windisch M (1996a) Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative cerebrolysin. J Neural Transm 47: 267–273CrossRefGoogle Scholar
  19. Hutter-Paier B, Frühwirth M, Windisch M (1996b) Ischemia induced loss of map2 is prevented by cerebrolysin and THA. Mol Biol Cell 7: 1278Google Scholar
  20. Kofler B, Erhart C, Erhart P, Harrer G (1990) A multidimensional approach in testing nootropic drug effects (cerebrolysin)-in press. Arch Geront Geriatr 10: 129–140CrossRefGoogle Scholar
  21. Lapchak PA, Araujo DM, Hefti F (1993) Regulation of hippocampal muscarinic receptor function by chronic nerve growth factor treatment in adult rats with fimbrial transections. Neuroscience 53/2: 379–394CrossRefGoogle Scholar
  22. Lapchak PA, Hefti F (1991) Emerging pharmacology of nerve growth factor. Prog Neuro-psychopharmacol Biol Psychiatry 15: 851–860CrossRefGoogle Scholar
  23. Lin JH, Hu GY, Tang XC (1997) Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Chung Kuo Yao Li Hsueh Pao 18/1: 6–10Google Scholar
  24. Lindner G (1975) Effects of brain extract and hydrolysate on nerve tissue in vitro. Z Mikrosk Anat Forsch 89: 815–823PubMedGoogle Scholar
  25. Lindsay RM (1994) Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 15/2: 249–251CrossRefGoogle Scholar
  26. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995) Neuro-degeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136: 107–122PubMedCrossRefGoogle Scholar
  27. Masliah E, Armasola F, Veinbergs I, Mallory M, Samuel W (1997) Neurotrophic and neuroprotective effects of cerebrolysin in experimental models of neuro-degeneration. Internal Research ReportGoogle Scholar
  28. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport 7: 1–4CrossRefGoogle Scholar
  29. Olson L, Nordberg A, von Holst H, et al (1992) Nerve growth factor affects HC-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient. J Neural Transm 4: 79–95CrossRefGoogle Scholar
  30. Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, Kotlan P, Paulitsch G, Reiner C, Stössl J, Zachhuber C, Mössier H (1997) Therapeutic results with cerebrolysin in the treatment of dementia. Wien Med Wochenschr 147: 426–431PubMedGoogle Scholar
  31. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27/1: 32–40CrossRefGoogle Scholar
  32. Satou T, Imano M, Akai F, Hashimoto S, Itoh T, Fujimoto M (1993) Morphological observation of effects of cerebrolysin on cultured neural cells. Adv Biosci 87: 195–196Google Scholar
  33. Satou T, Itoh T, Fujimoto M, Hashimoto S (1994) Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia. Jpn Pharmacol Ther 22/4: 205–212Google Scholar
  34. Seiger AKE, Nordberg A, von Holst H, Bäckmann L, Ebendal T, Alafuzoff I, Amberla K (1993) Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 57: 255–261PubMedCrossRefGoogle Scholar
  35. Shimazu S, Iwamoto N, Itoh T, Akasako A, Seki H, Jujimoto M (1991) Neurotrophic activity of cerebrolysin. Second International Springfield Symposium on Advantage in Alzheimer Therapy, Springfield, USA, p 51Google Scholar
  36. Siegfried K (1995) The efficacy of cholinergic drugs in patients with Alzheimer’s disease — focus on the aminoacridines. Humanpsychopharmacology 10: 89–96Google Scholar
  37. Sofroniew MV, Cooper JD (1993) Neurotrophic mechanisms and neuronal degeneration. Neurosciences 5: 285–249CrossRefGoogle Scholar
  38. Suchanek-Fröhlich H, Wunderlich E (1987) Randomized, plazebo-controlled, double-blind study with an amino-acid-peptid extract. Prakt Arzt 1: 1027–1034Google Scholar
  39. Wenzel JM, Grosse G, Lindner G, Kirsche W, Matthies H (1977) Die Wirkung von Aminosäuren auf die vitro-Differenzierung von Hippocampusneuronen — morphometrische und elektronenmikroskopische Untersuchung über Ribosomen, Protheinsynthese und Synaptogenese. J Hirnforsch 18: 357–371PubMedGoogle Scholar
  40. Yuen EC, Mobley WC (1996) Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 40/3: 346–354CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • M. Windisch
    • 1
  • A. Gschanes
    • 1
  • B. Hutter-Paier
    • 1
  1. 1.Institute of Experimental PharmacologyResearch Initiative EbeweGrazAustria

Personalised recommendations